OOIR: Observatory of International Research

Papers

(The H4-Index of Blood Reviews is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Beyond current treatment of Fanconi Anemia: What do advances in cell and gene-based approaches offer?	152
Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond	115
Pitfalls in laboratory monitoring of treatment in people with Haemophilia	111
Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders	110
Editorial Board	103
Not all LGL leukemias are created equal	87
Radiation and leukaemia: Which leukaemias and what doses?	77
Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach	65
Transplant-acquired allergy in HCT-recipients: Reference for clinical management	60
Clinical burden of hemophilia in older adults: Beyond bleeding risk	58
Artificial intelligence in sickle disease	54
Thalassaemia in China	52
The recipe for TACO: A narrative review on the pathophysiology and potential mitigation strategies of transfusion-associated circulatory overload	52
Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond	49
Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia	46
Breaking down frailty: Assessing vulnerability in acute myeloid leukemia	44
Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma	44
Chasing leukemia differentiation through induction therapy, relapse and transplantation	41
Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need	38
The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT	38
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies	36
Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103]	36
Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk	36
Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs	35
Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification	35

Endothelial cells: major players in acute myeloid leukaemia	34
Gut microbiome composition and dysbiosis in immune thrombocytopenia: A review of literature	33
Immune thrombocytopenia: A review of upfront treatment strategies	32
Preservation of fertility in female patients with hematologic diseases	32
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions	31
Harnessing multi-source data for individualized care in Hodgkin Lymphoma	31